Lansforsakringar Fondforvaltning AB publ Buys 5,388 Shares of Cencora, Inc. $COR

Posted by George Bondi on Jul 1st, 2026

Lansforsakringar Fondforvaltning AB publ increased its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 8.9% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 65,603 shares of the company’s stock after buying an additional 5,388 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Cencora were worth $20,608,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in COR. Vanguard Group Inc. grew its position in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after acquiring an additional 221,570 shares during the period. State Street Corp increased its stake in shares of Cencora by 1.3% during the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after purchasing an additional 115,191 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Cencora by 160.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Geode Capital Management LLC raised its holdings in shares of Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock worth $1,843,268,000 after purchasing an additional 169,055 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Cencora by 6.5% in the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after purchasing an additional 304,760 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.38% of the company’s stock.

Cencora Stock Up 0.6%

Shares of Cencora stock opened at $283.24 on Wednesday. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company’s 50 day moving average is $279.15 and its 200 day moving average is $321.28. The company has a market cap of $55.11 billion, a price-to-earnings ratio of 21.72, a price-to-earnings-growth ratio of 1.56 and a beta of 0.59.

Cencora (NYSE:COR – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period last year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its board has approved a stock buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s payout ratio is presently 18.40%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on COR. William Blair started coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Robert W. Baird dropped their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Barclays cut their price target on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. UBS Group lifted their price objective on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Citigroup lowered their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $367.75.

Get Our Latest Research Report on Cencora

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.